Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase I/II clinical study for its pipeline drug candidate, ZG005, aimed at treating advanced solid tumors.
ZG005 is an innovative anti PD-1/TIGIT bispecific antibody (BsAb) injection that is specifically targeted for the treatment of solid tumors. Notably, there is no similar product that has been approved globally to date. Encouraging results from previous studies have indicated that ZG005 demonstrates good tolerability, safety, and notable anti-tumor efficacy across various types of advanced solid tumors. Particularly remarkable effects have been observed in advanced cervical cancer patients.- Flcube.com
